The global atrophic vaginitis treatment market garnered a market value of US$ 2.57 Billion in 2022 and is expected to accumulate a market value of US$ 6 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033. Growth of the atrophic vaginitis treatment market can be attributed to increasing prevalence of the condition, the rising geriatric population, and the growing awareness about the importance of women's health. The market for atrophic vaginitis treatment registered a CAGR of 4.1% in the historical period 2018 to 2022
Atrophic vaginitis is a medical condition that occurs due to the thinning and inflammation of the vaginal walls, which is common in postmenopausal women. Atrophic vaginitis treatment market refers to the market for medications and therapies used to treat this condition.
The atrophic vaginitis treatment market includes a variety of products such as estrogen creams, vaginal moisturizers, and lubricants, among others. These products help to alleviate symptoms such as vaginal dryness, itching, and pain during intercourse.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 2.78 Billion |
| Anticipated Forecast Value (2033) | US$ 6 Billion |
| Projected Growth Rate (2023 to 2033) | 8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Atrophic vaginitis treatment reflected a value of 8% during the historical period, 2018 to 2022.
The market was driven by the increasing prevalence of atrophic vaginitis, the rising awareness of women's health, and the availability of effective treatment options. In addition, the increasing prevalence of atrophic vaginitis, the growing geriatric population, and the availability of new and innovative therapies is shaping the landscape for atrophic vaginitis treatment market.
Thus, the market for Atrophic vaginitis treatment is expected to register a CAGR of 4.1% in the forecast period 2023 to 2033.
Increasing prevalence of atrophic vaginitis along with rising awareness about women's health driving growth of market
The prevalence of atrophic vaginitis is increasing worldwide, especially in postmenopausal women. The condition affects approximately 50% of postmenopausal women, which is a significant population size. As the global population continues to age, the number of women affected by atrophic vaginitis is expected to increase. Women over the age of 65 are more likely to experience the condition.
There has been a growing awareness about the importance of women's health, leading to increased diagnosis and treatment of atrophic vaginitis. There are several effective treatment options available for atrophic vaginitis, such as estrogen creams, vaginal moisturizers, and lubricants. The availability of these treatments has increased demand for atrophic vaginitis treatment.
The increasing healthcare expenditure globally has led to increased access to healthcare services, including diagnosis and treatment of atrophic vaginitis.
Availability of Effective Treatment Options spurring growth of atrophic vaginitis treatment market
Estrogen Therapy: Estrogen therapy is one of the most effective treatments for atrophic vaginitis. It can be administered in the form of pills, creams, rings, or patches. Estrogen therapy can help to restore the vaginal tissues and alleviate symptoms such as vaginal dryness, itching, and pain during intercourse.
Vaginal Lubricants: Vaginal lubricants are used to reduce friction during intercourse and alleviate symptoms of vaginal dryness. They can be used alone or in combination with other treatments.
Vaginal Moisturizers: Vaginal moisturizers are used to hydrate and soothe the vaginal tissues. They can be used on a regular basis to alleviate symptoms of vaginal dryness.
Topical Estrogen Creams: Topical estrogen creams can be applied directly to the vaginal tissues to alleviate symptoms of atrophic vaginitis.
Osphena: Osphena is a non-estrogen prescription medication that can help alleviate symptoms of vaginal dryness and pain during intercourse.
Laser Therapy: Laser therapy is a new treatment option for atrophic vaginitis. It involves the use of laser technology to stimulate the growth of new tissue and improve the health of the vaginal tissues.
Principal Consultant
Side effects of hormone therapy along with cost of treatment derailing market growth
While hormone therapy is one of the most effective treatments for atrophic vaginitis, it can have potential side effects such as blood clots, stroke, and breast cancer. This can limit the use of hormone therapy, particularly in women who have a history of these conditions.
Despite growing awareness about women's health, many women may not be aware of the symptoms of atrophic vaginitis or the available treatment options. This can lead to underdiagnosis and undertreatment of the condition.
Some women may prefer to use alternative treatments such as herbal remedies or supplements, which may not have been adequately studied for their efficacy and safety in treating atrophic vaginitis. Some of the treatment options for atrophic vaginitis can be expensive, and not all women may have access to healthcare coverage that covers these costs.
Due to the intimate nature of the condition, some women may feel embarrassed or uncomfortable discussing their symptoms with their healthcare providers, which can lead to delays in diagnosis and treatment.
Availability of effective treatment favoring growth of market in North America
The North America atrophic vaginitis treatment market is a significant market, primarily driven by the high prevalence of the condition in the region. The market comprises the United States and Canada, which are expected to have a significant demand for atrophic vaginitis treatments.
The United States has a large population of postmenopausal women, which is the most susceptible group for atrophic vaginitis. As a result, the country has a significant demand for treatment options. The market is also supported by the presence of major pharmaceutical companies, such as Pfizer, Inc., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd, that offer a range of atrophic vaginitis treatments.
In addition, the increasing awareness about women's health and the availability of effective treatment options are expected to drive the growth of the North America atrophic vaginitis treatment market. Thus, North America is expected to possess 48% market share for atrophic vaginitis treatment market in 2023.
Presence of pharmaceutical companies boosting growth of market in Europe
The Europe atrophic vaginitis treatment market is a significant market, primarily driven by the high prevalence of the condition in the region. The market comprises the major countries in Europe, including the United Kingdom, Germany, France, Italy, Spain, and the rest of Europe.
The increasing aging population in Europe, particularly in Western Europe, is expected to contribute significantly to the growth of the market. Postmenopausal women, who are the most susceptible group for atrophic vaginitis, form a significant proportion of the aging population in Europe.
The market is also supported by the presence of major pharmaceutical companies that offer a range of atrophic vaginitis treatments, such as Pfizer, Inc., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.
Overall, the Europe atrophic vaginitis treatment market is expected to grow at a steady rate, driven by the increasing prevalence of the condition and growing demand for effective treatment options. The market is also likely to benefit from ongoing initiatives to raise awareness about women's health and the availability of treatment options. Thus, Europe is expected to possess 43% market share for atrophic vaginitis treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Availability of different estrogen-based therapy driving the growth of segment
Estrogen-based therapy is one of the most effective treatment options for atrophic vaginitis because it addresses the underlying cause of the condition. Atrophic vaginitis is primarily caused by a decrease in estrogen levels in the body, which can lead to vaginal dryness, itching, burning, and pain during sexual intercourse. Estrogen therapy helps to restore estrogen levels, which can improve the health of the vaginal tissues and relieve symptoms.
There are several forms of estrogen-based therapy available for atrophic vaginitis, including vaginal creams, tablets, rings, and patches. These products deliver estrogen directly to the vaginal tissues, which can help to restore vaginal health and relieve symptoms such as vaginal dryness, itching, and discomfort.
Estrogen therapy has been shown to be safe and effective for the treatment of atrophic vaginitis in numerous clinical studies. It is generally well-tolerated, and side effects are usually mild and temporary. Thus, by therapy type, estrogen based therapy is expected to possess 53% market share for atrophic vaginitis treatment market.
Key players in the atrophic vaginitis treatment are Shionogi, Duchesnay, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc, Theramex, Endoceutics, Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 2.78 Billion |
| Market Value in 2033 | US$ 6 Billion |
| Growth Rate | CAGR of 8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The CAGR for the market is 8% until 2033.
From 2018 to 2022, the market expanded at a 4.1% CAGR.
North America to hold 48% market share in 2023.
Shionogi, Duchesnay and Hormos Medical are key players.
Innovative therapies and expanding aging population present growth prospects.
1. Executive Summary | Atrophic Vaginitis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 5.3.1. Pelvic exam 5.3.2. Urine test 5.3.3. Acid balance test 5.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 6.3.1. Vaginal moisturizers 6.3.2. Water-based lubricants 6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033 7.3.1. Estrogen based drugs 7.3.2. Non-estrogen based drugs 7.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacy 8.3.2. Online Pharmacy 8.3.3. Retail Pharmacy 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Diagnosis 10.2.3. By Treatment 10.2.4. By Therapy Type 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Diagnosis 10.3.3. By Treatment 10.3.4. By Therapy Type 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Diagnosis 11.2.3. By Treatment 11.2.4. By Therapy Type 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Diagnosis 11.3.3. By Treatment 11.3.4. By Therapy Type 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Diagnosis 12.2.3. By Treatment 12.2.4. By Therapy Type 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Diagnosis 12.3.3. By Treatment 12.3.4. By Therapy Type 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Diagnosis 13.2.3. By Treatment 13.2.4. By Therapy Type 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Diagnosis 13.3.3. By Treatment 13.3.4. By Therapy Type 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Diagnosis 14.2.3. By Treatment 14.2.4. By Therapy Type 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Diagnosis 14.3.3. By Treatment 14.3.4. By Therapy Type 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Diagnosis 15.2.3. By Treatment 15.2.4. By Therapy Type 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Diagnosis 15.3.3. By Treatment 15.3.4. By Therapy Type 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Diagnosis 16.2.3. By Treatment 16.2.4. By Therapy Type 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Diagnosis 16.3.3. By Treatment 16.3.4. By Therapy Type 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Diagnosis 17.1.2.2. By Treatment 17.1.2.3. By Therapy Type 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Diagnosis 17.2.2.2. By Treatment 17.2.2.3. By Therapy Type 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Diagnosis 17.3.2.2. By Treatment 17.3.2.3. By Therapy Type 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Diagnosis 17.4.2.2. By Treatment 17.4.2.3. By Therapy Type 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Diagnosis 17.5.2.2. By Treatment 17.5.2.3. By Therapy Type 17.5.2.4. By Distribution Channel 17.6. United kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Diagnosis 17.6.2.2. By Treatment 17.6.2.3. By Therapy Type 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Diagnosis 17.7.2.2. By Treatment 17.7.2.3. By Therapy Type 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Diagnosis 17.8.2.2. By Treatment 17.8.2.3. By Therapy Type 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Diagnosis 17.9.2.2. By Treatment 17.9.2.3. By Therapy Type 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Diagnosis 17.10.2.2. By Treatment 17.10.2.3. By Therapy Type 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Diagnosis 17.11.2.2. By Treatment 17.11.2.3. By Therapy Type 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Diagnosis 17.12.2.2. By Treatment 17.12.2.3. By Therapy Type 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Diagnosis 17.13.2.2. By Treatment 17.13.2.3. By Therapy Type 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Diagnosis 17.14.2.2. By Treatment 17.14.2.3. By Therapy Type 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Diagnosis 17.15.2.2. By Treatment 17.15.2.3. By Therapy Type 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Diagnosis 17.16.2.2. By Treatment 17.16.2.3. By Therapy Type 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Diagnosis 17.17.2.2. By Treatment 17.17.2.3. By Therapy Type 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Diagnosis 17.18.2.2. By Treatment 17.18.2.3. By Therapy Type 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Diagnosis 17.19.2.2. By Treatment 17.19.2.3. By Therapy Type 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Diagnosis 17.20.2.2. By Treatment 17.20.2.3. By Therapy Type 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Diagnosis 17.21.2.2. By Treatment 17.21.2.3. By Therapy Type 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Diagnosis 18.3.3. By Treatment 18.3.4. By Therapy Type 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Shionogi 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Duchesnay 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Hormos Medical 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. QuatRx Pharmaceuticals 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Pantarhei Bioscience 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Mithra Pharmaceuticals 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. AMAG Pharmaceuticals 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Bayer HealthCare Pharmaceuticals Inc. 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Theramex 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Endoceutics, Inc. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Atrophic Vaginitis Treatment Market
